Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(11):788-789; doi:10.1093/jnci/94.11.788
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zujewski, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zujewski, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 11, 788-789, June 5, 2002
© 2002 Oxford University Press

EDITORIAL

"Build Quality in"—HER2 Testing in the Real World

Jo Anne Zujewski

Affiliation of author: J. Zujewski, National Cancer Institute, Bethesda, MD.

Correspondence to: Jo Anne Zujewski, M.D., National Cancer Institute, Center for Cancer Research, National Institutes of Health, Medicine Branch, 10 Center Dr., Bldg. 10, Rm. 12N/226, Bethesda, MD 20892 (e-mail: zujewski@nih.gov).

As I was preparing this editorial I read a very interesting article titled "Being Misread: A Lesson in Vigilance" by Clare Crawford-Mason (1). This poignant story describes how the author made a sound medical decision to avoid a hysterectomy using the principles established by the late quality guru, W. Edwards Deming (2). The question she asked herself based on Deming's teachings was, "Would you really make a decision about something as important as this with a single data point—just one reading of one slide?" This is the issue at hand today, with the publication of two . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
K.-h. Cheng, J. F. Ponte, and S. Thiagalingam
Elucidation of Epigenetic Inactivation of SMAD8 in Cancer Using Targeted Expressed Gene Display
Cancer Res., March 1, 2004; 64(5): 1639 - 1646.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. B. Schiffer, S. Gebhard, C. K. Heimerdinger, A. Heling, J. Hast, U. Wollscheid, B. Seliger, B. Tanner, S. Gilbert, T. Beckers, et al.
Switching Off HER-2/neu in a Tetracycline-Controlled Mouse Tumor Model Leads to Apoptosis and Tumor-Size-Dependent Remission
Cancer Res., November 1, 2003; 63(21): 7221 - 7231.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. Vincent-Salomon, G. MacGrogan, J. Couturier, L. Arnould, and S. Mathoulin-Pelissier
Re: HER2 Testing in the Real World
J Natl Cancer Inst, April 16, 2003; 95(8): 628 - 628.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
R. L. Camp, M. Dolled-Filhart, B. L. King, and D. L. Rimm
Quantitative Analysis of Breast Cancer Tissue Microarrays Shows That Both High and Normal Levels of HER2 Expression Are Associated with Poor Outcome
Cancer Res., April 1, 2003; 63(7): 1445 - 1448.
[Abstract] [Full Text] [PDF]